Phase I-II open label multicenter study of PD0332991 in <i>BRAF<sup>V600mut</sup></i> metastatic melanoma patients harboring <i>CDKN2A</i> loss and RB1 expression and treated with vemurafenib.
Baptiste Louveau(Inserm), Célèste Lebbé(Inserm), Matthieu Resche‐Rigon(Inserm), Thierry Lesimple, Annick Tibi(Assistance Publique – Hôpitaux de Paris), Keyvan Rezaï(Hôpital René Huguenin), Didier Bouton(Assistance Publique – Hôpitaux de Paris), Mona Amini‐Adlé(Centre Léon Bérard), Zineb Ghrieb(Assistance Publique – Hôpitaux de Paris), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Samuel Huguet(Institut Curie), Fanélie Jouenne(Inserm), Laetitia Da Meda(Assistance Publique – Hôpitaux de Paris), Julie Delyon(Inserm), Maxime Battistella(Peter MacCallum Cancer Centre), Samia Mourah(Assistance Publique – Hôpitaux de Paris), Barouyr Baroudjian, Marc Pracht(Canadian Partnership Against Cancer)
Cited by 5
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k